US59156R1086 - Common Stock

**MET** gets a fundamental rating of **4** out of 10. The analysis compared the fundamentals against 143 industry peers in the **Insurance** industry. Both the profitability and financial health of **MET** have multiple concerns. **MET** is valued correctly, but it does not seem to be growing.

In the past year **MET** was profitable.

In the past year **MET** had a positive cash flow from operations.

Looking at the **Return On Assets**, with a value of **0.33%**, **MET** is doing worse than **64.08%** of the companies in the same industry.

The **Return On Equity** of **MET** (**8.26%**) is comparable to the rest of the industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.33% | ||

ROE | 8.26% | ||

ROIC | 0.52% |

ROA(3y)0.61%

ROA(5y)0.67%

ROE(3y)8.08%

ROE(5y)8.47%

ROIC(3y)0.78%

ROIC(5y)0.84%

In the last couple of years the **Profit Margin** of **MET** has declined.

With a **Operating Margin** value of **6.19%**, **MET** perfoms like the industry average, outperforming **42.96%** of the companies in the same industry.

In the last couple of years the **Operating Margin** of **MET** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 6.19% | ||

PM (TTM) | 3.3% | ||

GM | N/A |

OM growth 3Y-21.66%

OM growth 5Y-6.25%

PM growth 3Y-25.67%

PM growth 5Y-11.69%

GM growth 3YN/A

GM growth 5YN/A

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), **MET** is destroying value.

Compared to 1 year ago, **MET** has less shares outstanding

Compared to 5 years ago, **MET** has less shares outstanding

The Debt to FCF ratio of **MET** is **1.71**, which is an excellent value as it means it would take **MET**, only **1.71** years of fcf income to pay off all of its debts.

Although **MET** does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.73 | ||

Debt/FCF | 1.71 | ||

Altman-Z | N/A |

ROIC/WACC0.07

WACC7.58%

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | N/A | ||

Quick Ratio | N/A |

The earnings per share for **MET** have decreased by **-6.70%** in the last year.

The **Earnings Per Share** has been growing by **9.03%** on average over the past years. This is quite good.

The **Revenue** has been growing slightly by **2.32%** on average over the past years.

EPS 1Y (TTM)-6.7%

EPS 3Y3.83%

EPS 5Y9.03%

EPS growth Q2Q61.16%

Revenue 1Y (TTM)-12.37%

Revenue growth 3Y0.07%

Revenue growth 5Y2.32%

Revenue growth Q2Q-28.8%

The **Earnings Per Share** is expected to grow by **3.18%** on average over the next years.

Based on estimates for the next years, **MET** will show a small growth in **Revenue**. The Revenue will grow by **0.92%** on average per year.

EPS Next Y10.16%

EPS Next 2Y16.6%

EPS Next 3Y14.97%

EPS Next 5Y3.18%

Revenue Next Year-7.25%

Revenue Next 2Y-2.09%

Revenue Next 3Y-0.08%

Revenue Next 5Y0.92%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

With a **Price/Earnings** ratio of **9.21**, the valuation of **MET** can be described as very reasonable.

Based on the **Price/Earnings** ratio, **MET** is valued a bit cheaper than the industry average as 66.90% of the companies are valued more expensively.

The average S&P500 **Price/Earnings** ratio is at **24.54**. **MET** is valued rather cheaply when compared to this.

A **Price/Forward Earnings** ratio of **6.89** indicates a rather cheap valuation of **MET**.

Based on the **Price/Forward Earnings** ratio, **MET** is valued a bit cheaper than 73.94% of the companies in the same industry.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **20.22**, **MET** is valued rather cheaply.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 9.21 | ||

Fwd PE | 6.89 |

Based on the **Price/Free Cash Flow** ratio, **MET** is valued a bit cheaper than the industry average as 78.87% of the companies are valued more expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 4.31 | ||

EV/EBITDA | 11.01 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as **MET**'s earnings are expected to grow with **14.97%** in the coming years.

PEG (NY)0.91

PEG (5Y)1.02

EPS Next 2Y16.6%

EPS Next 3Y14.97%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.28% |

The dividend of **MET** has a limited annual growth rate of **5.49%**.

Dividend Growth(5Y)5.49%

Div Incr Years1

Div Non Decr Years1

DP83.35%

EPS Next 2Y16.6%

EPS Next 3Y14.97%

**METLIFE INC**

NYSE:MET (12/8/2023, 7:04:00 PM)

After market: 64.09 0 (0%)**64.09**

**+0.63 (+0.99%) **

Chartmill FA Rating

GICS SectorFinancials

GICS IndustryGroupInsurance

GICS IndustryInsurance

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap47.44B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.28% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 9.21 | ||

Fwd PE | 6.89 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.91

PEG (5Y)1.02

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.33% | ||

ROE | 8.26% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 6.19% | ||

PM (TTM) | 3.3% | ||

GM | N/A | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.1

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.73 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | N/A | ||

Quick Ratio | N/A | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-6.7%

EPS 3Y3.83%

EPS 5Y

EPS growth Q2Q

EPS Next Y10.16%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-12.37%

Revenue growth 3Y0.07%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y